Transcriptomics

Dataset Information

17

Expression data from colonic biopsy samples of infliximab treated UC patients


ABSTRACT: A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. Genes affected are primarily involved with inflammatory response, cell-mediated immune responses, and cell-to-cell signaling. Infliximab non-responders had a molecular phenotype that closely resembled that of untreated patients with UC. Unlike responders, non-responders do not effectively modulate TH1, TH2, and TH17 pathways. Gene expression can differentiate placebo and infliximab responders. Patients with moderate-to-severe, active UC were treated with infliximab or placebo at weeks 0, 2, 6 and every 8 weeks thereafter. Biopsy samples (n=113) were collected from 48 patients at baseline, weeks 8 and 30 for RNA extraction and microarray analysis.

ORGANISM(S): Homo sapiens  

SUBMITTER: K Li   Sarah Sague  Xiao-Yu Song  Katherine Li  Gary Toedter  Paul Rutgeerts  C C Huang  Frédéric Baribaud  Colleen Marano  Keying Ma 

PROVIDER: E-GEOD-23597 | ArrayExpress | 2011-07-21

SECONDARY ACCESSION(S): GSE23597PRJNA131739

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.

Toedter Gary G   Li Katherine K   Marano Colleen C   Ma Keying K   Sague Sarah S   Huang C Chris CC   Song Xiao-Yu XY   Rutgeerts Paul P   Baribaud Frédéric F  

The American journal of gastroenterology 20110329 7


OBJECTIVES: Infliximab has been shown to induce clinical response and remission in ulcerative colitis (UC). To characterize the biological response of patients to infliximab, we analyzed the mRNA expression patterns of mucosal colonic biopsies taken from UC patients enrolled in the Active Ulcerative Colitis Trial 1 (ACT1) study. METHODS: Biopsies were obtained from 48 UC patients before treatment with 5 or 10 mg/kg infliximab, and at 8 and 30 weeks after treatment (n = 113 biopsies). Global gene  ...[more]

Similar Datasets

2011-07-22 | GSE23597 | GEO
2009-09-05 | E-GEOD-12251 | ArrayExpress
2013-04-01 | E-GEOD-45468 | ArrayExpress
2014-08-04 | E-GEOD-12251 | ExpressionAtlas
2009-08-25 | GSE12251 | GEO
2007-10-09 | E-GEOD-8350 | ArrayExpress
2007-10-10 | GSE8350 | GEO
2010-01-06 | E-GEOD-14580 | ArrayExpress
2010-01-07 | GSE14580 | GEO
2014-12-22 | E-GEOD-51785 | ArrayExpress